EyePoint Pharmaceuticals, Inc. — Director's Dealing 2022

Sep 9, 2022

SEC Form 4/A — Form 4/A

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2021-11-01

Reporting Person: Duker Jay S. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Stock Option (Right to Buy)	$11.47	A	239700.00	Acquired	2031-11-01	Common Stock (239700.00)	Direct

Footnotes

F1: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months.

F2: Due to an administrative error, the Reporting Person's previous Form 4 filed on November 3, 2021 incorrectly reported the Reporting Person receiving an option grant of 305,000 shares of common stock when it should have been reported as 239,700 shares of common stock.